Clinical Trials Logo

Filter by:
NCT ID: NCT00633477 Terminated - Sepsis Clinical Trials

Efficacy and Safety of Resatorvid in Patients With Sepsis-induced Cardiovascular and Respiratory Failure

Start date: February 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the effect of resatorvid on subjects with sepsis.

NCT ID: NCT00633204 Active, not recruiting - Bladder Cancer Clinical Trials

Peptide Vaccine Focusing on Prevention of the Recurrence for Bladder Cancer

Start date: February 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the clinical efficacy for the prevention of the recurrence for bladder cancer after TUR-Bt

NCT ID: NCT00632554 Completed - Chronic Disease Clinical Trials

The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic Pneumonia

Start date: June 2008
Phase: Phase 4
Study type: Interventional

A comparison of 3 months-prednisolone administration with 6 months-prednisolone therapy in the treatment of chronic eosinophilic pneumonia. Three months-prednisolone administration may be as effective as 6 months-therapy.

NCT ID: NCT00632333 Recruiting - Esophageal Cancer Clinical Trials

Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer

Start date: February 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and immune response of multiple peptides (URLC10, TTK, KOC1 VEGFR1, and VEGFR2) emulsified with Montanide ISA51 in combination with chemotherapy (CDDP, 5-FU) plus radiation therapy in treating patients with unresectable, advanced or recurrent esophageal cancer.

NCT ID: NCT00631579 Completed - Lymphoma Clinical Trials

Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma

Start date: April 2003
Phase: Phase 2
Study type: Interventional

The primary objectives of the study are to evaluate the safety and the efficacy in patients with malignant lymphoma or acute leukemia who are repeatedly administered for SR29142 5 days in two dosage groups. Secondary objectives are to determine the pharmacokinetic (PK) parameters of SR29142 , to assess anti-SR29142 antibody production in patients with malignant lymphoma and acute leukemia, and to estimate the optimal dosage of SR29142 for Japanese patients from the results of efficacy and safety evaluations.

NCT ID: NCT00631475 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443

BUILD OL
Start date: April 2008
Phase: Phase 3
Study type: Interventional

This Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 (NCT00391443) will asses the long term safety and tolerability of bosentan in patients with idiopathic pulmonary fibrosis (IPF).

NCT ID: NCT00631410 Completed - Clinical trials for Colorectal Neoplasms

Study Of Sunitinib In Combination With Folfox In Patients With Colorectal Cancer

Start date: January 2008
Phase: Phase 1
Study type: Interventional

To assess the safety and tolerability of sunitinib when administered in combination with modified FOLFOX6 in Japanese patients with metastatic colorectal cancer in the first-line treatment setting.

NCT ID: NCT00631163 Completed - Clinical trials for Transfusional Hemosiderosis

Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis

Start date: October 2007
Phase: Phase 2
Study type: Interventional

The overall purpose of this trial is to further evaluate the efficacy and safety of deferasirox, dosed initially according to the transfusional iron intake, in patients with transfusion dependant anemia related to disorders other than β-thalassemia and sickle cell disease. During the study, the dose will be adjusted based on serum Ferritin.The overall purpose of the extension is to allow further treatment of patients who have already completed the core study, and to enable collection of long term efficacy and safety data. Patients will continue to receive Deferasirox at the dose they received at the end of the core study.

NCT ID: NCT00630058 Completed - Hepatitis C Clinical Trials

A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C

Start date: April 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, pharmacokinetics, HCV RNA kinetics, and other viral characteristics after administration of two arms of MP-424 in combination with Peginterferon Alfa 2b (PEG-IFN-a-2b) and Ribavirin (RBV) to patients with chronic hepatitis C.

NCT ID: NCT00628862 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Evaluation of Efficacy and Safety of Formoterol in Patients With COPD Compared With Placebo in Patients in Japan, EU

OCEAN
Start date: December 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to show the efficacy and safety of formoterol for the maintenance treatment of patients with COPD compared with placebo in patients in Japan and in European countries during 12 weeks.